GlassScriptPhysician profile
Gerard L Hershewe
NPI 1598785065
$1,789.43
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,058 · 2020: $40.94 · 2021: $630 · 2022: $60.80.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $346.78 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $282.34 | 2019 | |
| Horizon Therapeutics Plc | $203.76 | 2021 | |
| Amgen INC. | $153.54 | 2019-2021 | |
| Abbvie INC. | $151.87 | 2021-2022 | |
| Allergan, INC. | $106.96 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $102.88 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $96.73 | 2019-2021 | |
| Merz North America, INC. | $63.80 | 2019 | |
| Genentech USA, INC. | $45.75 | 2019 | |
| Assertio Therapeutics, INC. | $35.98 | 2019 | |
| Merz Pharmaceuticals, LLC | $33.18 | 2021 | |
| Lilly USA, LLC | $32.94 | 2021 | |
| Genzyme Corporation | $32.88 | 2019 | |
| Supernus Pharmaceuticals, INC. | $30.39 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $29.67 | 2022 | |
| Shire North American Group INC | $23.66 | 2019 | |
| Acadia Pharmaceuticals INC | $16.32 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerard Hershewe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.